Apex Laboratory · Compound explained · Evidence checked September 8, 2026
SLU-PP-332 is a small molecule, not a peptide. Researchers use it to activate estrogen-related receptors, or ERRs, and investigate how cells regulate energy use. It produced exercise-related changes in mice, but those findings do not establish an exercise replacement, fat-loss treatment or safe regimen for people.
The useful question is not just whether it “works.” Ask what changed: receptor activity, a gene signal, mouse fat accumulation, exercise endurance or an actual human outcome. Those measurements answer different questions.
What is SLU-PP-332?
It is a synthetic organic compound in an acylhydrazone chemical series. Unlike a peptide, it has no amino-acid sequence. The PubChem reference record lists formula C18H14N2O2 and molecular weight about 290.3 g/mol. A website placing it under a peptide category does not change that chemistry.
The estrogen-related receptors are distinct from the classical estrogen receptors. Their similar names do not mean that SLU-PP-332 is estrogen, an estrogen supplement or a demonstrated way to raise estrogen levels.
ERRs help control gene-expression programs associated with cellular energy. Receptor biology review · Metabolic roles and limitations
How does SLU-PP-332 work?
An agonist activates a receptor. “Pan-ERR” means activity across ERR alpha, beta and gamma. These are nuclear receptors: proteins that help regulate transcription, the process of reading genes. ERRs work with other regulatory proteins, including PGC-1 coactivators; this is a network, not one universal metabolic switch.
Three targets. Different assay potencies.
EC50 values reported in the original full-length receptor reporter assay. A lower value means less compound was needed for the assay’s half-maximal response. These are laboratory concentrations, not human doses, receptor occupancy or percentages of benefit.
The original paper linked the acute exercise-response gene program to ERR alpha. The cardiac studies found an important ERR gamma dependency. That difference is one reason not to assume all three receptors contribute equally in every tissue. Original agonist study · Cardiac dependency experiments
Does it reproduce exercise?
Only selected features have been reproduced in the tested models. The original mouse work reported more oxidative muscle fibers and improved treadmill endurance. It did not reproduce every cardiovascular, mechanical, neurological and training adaptation of exercise. Nor does an oxidative-fiber change establish muscle growth in a person.
Autophagy—the processing and recycling of cellular material—is another studied pathway. Experiments in neonatal rat heart cells and a mouse muscle-cell line linked ERR activation to TFEB, a regulator of that pathway. This is cellular mechanism evidence, not proof of whole-body rejuvenation. ERR–TFEB study
What were the fat-loss and metabolic results?
The obesity paper studied different mouse populations. Its results are more informative when the unchanged measurements remain visible beside the positive ones. Billon and colleagues, metabolic-syndrome study.
Ordinary-diet mice
After 28 days, total bodyweight did not differ between groups. The treated mice accumulated less fat and showed increased fatty-acid oxidation. Food intake and lean mass did not differ.
A change in fuel use was not the same as a change on the scale in this cohort.
Diet-induced obesity
In the high-fat-diet cohort, seven male mice per group were followed for 28 days.
These are approximate fat-mass gains in a particular mouse experiment—not kilograms lost, a percentage of human bodyweight or an expected personal result.
The high-fat-diet mice also showed improvements in some metabolic measures, while fed blood glucose and lean mass did not significantly change. A genetically obese mouse model was studied separately. None of these cohorts supplies a reliable human before-and-after forecast.
“Exercise mimetic” also describes compounds with different targets. The often-repeated 44% endurance increase in a 2008 paper belonged to AICAR in sedentary mice; that experiment did not test SLU-PP-332. A number cannot be transferred simply because both compounds share a nickname. Original AICAR and PPAR study
Has SLU-PP-332 been tested in humans?
A 2025 study used human-derived muscle cells, but the people were not given SLU-PP-332. The distinction is easy to miss if a summary calls it a “human study.” Bonanni and colleagues.
- 20 women provided muscle tissueParticipants undergoing hip replacement were grouped by self-reported activity: ten active and ten inactive.
- Cells were grown from biopsiesResearchers established primary myoblast cultures from the inactive participants’ tissue.
- The cultures received SLU-PP-332Cellular stress markers, protein expression and differentiation were examined outside the body.
- No human treatment outcome followedThe study did not measure how the compound affected participants’ strength, weight, symptoms or safety.
Treated cultures showed lower NOX4 and changes in SIRT1, PGC-1 alpha, ERR alpha and other measured proteins, alongside greater myotube formation. The active-versus-inactive participants’ clinical differences were observations at baseline, not drug effects. The authors described the work as a pilot and called for further investigation.
On September 8, 2026, exact-name ClinicalTrials.gov searches for SLU-PP-332 and SLU-PP-915 returned no records. A broader ERR-agonist query also returned none. This is a dated search finding, not proof about every unpublished project or every registry worldwide.
What do we know about heart, liver and kidney effects?
There is no measured human side-effect rate in the studies reviewed here. Animal disease experiments can identify promising effects and unresolved questions, but they cannot certify safety in a healthy person.
Better heart function did not mean less heart enlargement
In a mouse pressure-overload model, SLU-PP-332 and SLU-PP-915 improved ejection fraction and survival, yet neither prevented cardiac hypertrophy. The same report found that SLU-PP-915 improved stroke volume and cardiac output, whereas SLU-PP-332 did not improve those measures.
The authors also identified unresolved questions about cardiac relaxation and ERR signaling. This is neither a clinical heart-protection claim nor proof that SLU-PP-332 causes heart enlargement in people. Primary cardiac report
The obesity-model paper did not report elevated liver enzymes in its high-fat-diet cohort. That limited observation cannot rule out human liver injury, interactions or problems after longer exposure. A separate experiment in 21-month-old mice reported improved kidney inflammatory and mitochondrial measures after eight weeks. It did not establish a kidney treatment or general longevity benefit. Aging-kidney experiment
A 2026 systematic review summarized earlier animal and cell studies. Its statement about no evident toxicity in those models is not a new human safety trial. A long-term safety assessment would need direct evidence about exposure, organs, interactions and populations that these experiments do not supply. Review and its stated clinical-evidence gap
SLU-PP-332 versus SLU-PP-915: what changed?
SLU-PP-915 is a different molecule, developed through another chemical series. The 2023 medicinal-chemistry report described a thiophene-based series and the boronic-acid-containing lead. It is not simply SLU-PP-332 put into a capsule. Original SLU-PP-915 development.
SLU-PP-332
- Target family
- Pan-ERR agonist.
- Mouse exercise evidence
- Reported after experimental exposure outside the oral route.
- Oral limitation
- The later comparison paper explicitly describes it as lacking oral bioavailability.
- Human exposure evidence
- Not established in the source set and registry searches reviewed here.
SLU-PP-915
- Target family
- Pan-ERR agonist.
- Mouse exercise evidence
- Reported by both injected and oral routes in the comparison study.
- Oral finding
- Oral mouse activity was reported with systemic exposure taken into account.
- Human exposure evidence
- Not established in the source set and registry searches reviewed here.
The 2026 exercise comparison found similar mouse running performance with the two compounds under its injected-exposure comparison, and oral activity for SLU-PP-915. Both induced the exercise-responsive gene Ddit4. Those results support further compound development; they do not establish human capsule absorption or a clinical winner. Direct comparison report.
How long does SLU-PP-332 take to work?
The reviewed studies do not establish a human onset time, duration of effect or plasma half-life. A cell response, a mouse treadmill result and an in-vitro metabolism measurement cannot determine when a person should take it before exercise or sleep.
A reported half-life needs its test system
A 2026 chemistry paper reported a 31.3-minute hepatic-microsomal half-life for SLU-PP-332 and very low kinetic solubility under its assay conditions. Microsomes are a laboratory preparation used to examine metabolism. That number is not a measured human plasma half-life and cannot set a dosing interval. Structure–activity and assay report.
Two separate analytical studies identified transformation products in human-liver test systems: one reported nine SLU-PP-332 metabolites, another 22. Their methods and counts differ; neither administered the compound to volunteers or measured how long a person’s effect lasted. Comparative metabolism study · Additional metabolite identification.
What is still unknown?
The source set does not establish a validated human regimen, benefit, interaction profile or short- and long-term safety. This guide does not identify an approved medicine or prescribing label for SLU-PP-332. A research-catalog listing, a registered chemical identity and an animal-paper result are different kinds of information.
For any claimed benefit, check the compound, experimental unit, comparison and endpoint. “Pan-ERR” describes target activity; “exercise mimetic” describes selected model findings. Neither term supplies a personal treatment plan. Research materials are not for human or veterinary use.
Reading a research-material record
The SLU-PP-332 material page is the place to check the current listed configuration. Its name or an analytical percentage does not establish equivalence to a paper’s test article. The Lab Verified library and COA reading guide explain how identity, chromatographic area and measured content answer separate questions.
For adjacent mechanisms, the MOTS-c guide describes an actual peptide with a different evidence base; the specialty-compound hub provides the broader library context. Shared metabolic language does not make those compounds interchangeable or validate combining them.
Frequently Asked Questions
Is SLU-PP-332 a peptide?
No. SLU-PP-332 is a synthetic small molecule in an acylhydrazone chemical series. It has a chemical structure rather than an amino-acid sequence. A catalog category does not determine its chemical identity.
What are the benefits of SLU-PP-332?
Published studies report selected changes in cellular metabolism, mouse endurance and mouse disease models. Those are preclinical findings, not demonstrated benefits for people. The outcome and experimental model should accompany every claim.
Has SLU-PP-332 been tested in humans?
A study exposed human-derived muscle-cell cultures outside the body, not the participants who provided the biopsies. No human exposure study was identified in the reviewed source set, and exact-name ClinicalTrials.gov searches returned no records on September 8, 2026.
Does SLU-PP-332 burn fat or build muscle?
Mouse studies found changes in fat accumulation and oxidative muscle properties, while some measurements remained unchanged. Human fat loss, muscle growth and strength benefits are not established by those experiments.
Is SLU-PP-332 bad for the heart or liver?
The reviewed research cannot determine its human cardiac or liver risk. In a mouse pressure-overload model, heart function improved without reversal of hypertrophy. Limited liver-enzyme findings in another mouse cohort do not rule out human toxicity.
Does oral SLU-PP-332 work like SLU-PP-915?
They are different molecules. The later comparison describes SLU-PP-332 as lacking oral bioavailability and reports oral activity for SLU-PP-915 in mice. That does not establish human capsule absorption or make their formulations interchangeable.
What is the half-life of SLU-PP-332?
The reviewed evidence does not establish a human plasma half-life. The 31.3-minute value in one chemistry paper is a hepatic-microsomal laboratory result. It cannot determine a personal dosing interval or duration of effect.
When should SLU-PP-332 be taken before exercise or sleep?
The studies reviewed here do not establish a safe human timing or dosing schedule. A mouse response or a laboratory metabolism measurement cannot supply one. Research materials are not for human or veterinary use.
References and primary sources
Original experiments, later analytical work and background reviews are identified separately in the text. ClinicalTrials.gov observations were checked September 8, 2026. The source list includes animal and cell research; it is not a list of human trials.
- Giguère V et al. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocrine reviews. 2008. PMID 18664618.
- Audet-Walsh É et al. The multiple universes of estrogen-related receptor α and γ in metabolic control and related diseases. Acta pharmacologica Sinica. 2015. PMID 25500872.
- Billon C et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS chemical biology. 2023. PMID 36988910.
- Xu W et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024. PMID 37961903.
- Billon C et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. The Journal of pharmacology and experimental therapeutics. 2024. PMID 37739806.
- Losby M et al. The Estrogen Receptor-Related Orphan Receptors Regulate Autophagy through TFEB. Molecular pharmacology. 2024. PMID 39168657.
- Wang XX et al. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. The American journal of pathology. 2023. PMID 37717940.
- Bonanni R et al. Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study. Frontiers in physiology. 2025. PMID 40692696.
- Okda HE et al. Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling. International journal of biological macromolecules. 2026. PMID 41850449.
- Narkar VA et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008. PMID 18674809.
- de Souza-Lima J et al. [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications]. Revista medica de Chile. 2026. PMID 42024694.
- Billon C et al. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. The Journal of pharmacology and experimental therapeutics. 2026. PMID 41421047.
- Möller T et al. In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. Rapid communications in mass spectrometry : RCM. 2026. PMID 41588687.
- Avliyakulov NK et al. Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes. Drug testing and analysis. 2026. PMID 41688415.
- Hampton CS et al. Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915. European journal of medicinal chemistry. 2023. PMID 37421886.
